ReviewEye (London, England)2022
Evolving treatment paradigms for PCV.
Review in Eye (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2023Pooled it
- Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.JAMA ophthalmology · 2026Trial
- Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.Japanese journal of ophthalmology · 2023Trial
- Beyond Typical AMD: A Vodcast Exploring the Clinical and Therapeutic Landscape of PCV.Advances in therapy · 2026Article
- Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.Ophthalmology and therapy · 2026Article
- The aging eye: navigating molecular mechanisms and innovative interventions.Biogerontology · 2026Review
- Long-Term Management of Polypoidal Choroidal Vasculopathy: A Narrative Review.Ophthalmology and therapy · 2026Review
- Anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy.Indian journal of ophthalmology · 2026Review
- OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration.BMC ophthalmology · 2026Article
- Prevalence of Polypoidal Choroidal Vasculopathy Beyond Recalcitrant Macular Neovasculopathies in a European AMD Cohort and Therapeutic Response to Brolucizumab.Journal of clinical medicine · 2026Article
- One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study.Eye (London, England) · 2025Article
- OCT and OCTA quantitative metrics for polypoidal choroidal vasculopathy.BMJ open ophthalmology · 2025Review
- Localization of Polypoidal Choroidal Vasculopathy in Fluorescein Angiography Using Semisupervised Deep Learning With Labeled and Unlabeled Images.Translational vision science & technology · 2025Article
- Pachychoroid disease: review and update.Eye (London, England) · 2025Review
- Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy.BMC ophthalmology · 2024Article
- Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.Ophthalmology and therapy · 2024Article
- Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management.Eye (London, England) · 2024Review
- Optical Coherence Tomography Angiography: A 2023 Focused Update on Age-Related Macular Degeneration.Ophthalmology and therapy · 2024Review
- Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept.Scientific reports · 2024Article
- Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression.BMC ophthalmology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD (nAMD) that accounts for a significant proportion of nAMD cases worldwide, and particularly in Asia. Contemporary PCV treatment strategies have closely followed those used in typical nAMD, though there are significant gaps in knowledge on PCV management and it remains unclear if these strategies are appropriate. Current clinical trial data suggest intravitreal anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy is effective in managing haemorrhage and exudation in PCV, although the optimal treatment interval, including as-needed and treat-and-extend approaches, is unclear. Newer imaging modalities, including OCT angiography and high-resolution spectral domain OCT have enabled characterisation of unique PCV biomarkers that may provide guidance on how and when treatment and re-treatment should be initiated. Treatment burden for PCV is a major focus of future therapeutic research and several newly developed anti-VEGF agents, including brolucizumab, faricimab, and new modes of drug delivery like the port delivery system, offer hope for dramatically reduced treatment burden for PCV patients. Beyond anti-VEGF therapy, recent developments in our understanding of PCV pathophysiology, in particular the role of choroidal anatomy and lipid mediators in PCV pathogenesis, offer new treatment avenues that may become clinically relevant in the future. This article explores the current management of PCV and more recent approaches to PCV treatment based on an improved understanding of this unique disease process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.